peripheral cholesterol synthesis(DHCR7); 3, intestinal cholesterol synthesis (DHCR7); 4, dietary cholesterol 8 4 intake (NPC1L1); 5, hepatic uptake of cholesterol from LDL (LDLR,APOB,APOE); 6, VLDL-C secretion 8 5 (MTTP); 7, peripheral uptake of cholesterol from LDL (LDLR,APOB,APOE); 8, peripheral cholesterol 8 6 transport to HDL (ABCA1); 9, HDL-associated cholesterol esterification (LCAT); 10, hepatic HDL-CE 8 7 uptake (SCARB1); 11, intestinal chylomicron cholesterol secretion (MTTP); 12, peripheral cholesterol loss; 8 8
13, hepatic HDL-FC uptake (MTTP); 14, biliary cholesterol excretion (ABCG8,NPC1L1); 15, fecal 8 9 cholesterol excretion; 16, intestinal cholesterol transport to HDL (ABCA1); 17, hepatic cholesterol transport 9 0 to HDL (ABCA1); 18, hepatic cholesterol catabolism (CYP7A1); 19, hepatic cholesterol esterification 9 1 (SOAT2); 20, intestinal cholesterol esterification (SOAT2); and 21, CE transfer from HDL to LDL (CETP). 9 2 9 3 9 4 CE transfer from HDL to LDL CETP Reaction rates present in the model and the associated biological process they represent, also the main genes 9 6 involved in the process are reported [6] , [7] . 9 7 9 8
Model implementation
The algorithm of the available physiologically based kinetic mode [5] , was implemented in R language [8] . 1 0 0
The deSolve package [9] was used for solving differential equations. To improve performance in predicting genetic mutations' effect on cholesterol levels, f mut parameters, each 1 0 6 one related to a particular gene mutation and rates of the model, had been trained on phenotype data of a 1 0 7 custom dataset of patients. The Levenberg-Marquardt minimization method has been used to estimate the f mut 1 0 8 parameters able to minimize the difference between predicted and experimentally measured level of HDL 1 0 9 and LDL, divided by the control, intended as level of cholesterol of the model when no mutation is present 1 1 0 (Equation 1 and 2). Exceptions are patients affected by mutations on the DHCR7 genes where only total 1 1 1 cholesterol (TC) levels were found in literature. In this case the difference between real and predicted total 1 1 2 cholesterol rate where taken in account (Equation 3).
The optimized f mut parameters are reported in Table 2 . 1 1 9 Prediction performance were tested on a dataset retrieved form literature [6] . The dataset is the same one 1 4 6 used to test performance of the former version of the model. This test set has been used in order to highlight 1 4 7 performance comparison between the versions of the algorithm. The effect of a genetic mutation was 1 4 8 simulated for each individual of the dataset until a steady state was reached (fixed threshold: 1000 days). 1 4 9
Predicted HDL, LDL and total cholesterol were than compared to experimental data. 1 5 0
Test set
Test set is composed by patients affected by 10 mutations. All mutations affects genes present in the training 1 5 2 set of this work. The first group of mutations maps on the LDLR, APOB and APOE genes, involved in Mutations on the ABCA1 can cause marked HDL cholesterol levels deficiency as reported for different 1 5 6 disease like hypoalphaliproproteinemia or Tangier disease [3] . CETP is a protein involved in the transport 1 5 7 of cholesterol esters from HDL to LDL, deficiency of this protein can cause a marked increase of HDL levels 1 5 8
[3]. LCAT is a gene involved in cholesterol esterification in HDL particles, mutation on this gene can cause 1 5 9 LCAT deficiency, characterized by low levels of HDL and LDL cholesterol [3] . Patients with mutations in 1 6 0 heterozygous or homozygous form has been included in the training set. DHCR7 gene is responsible for the 1 6 1 last step of the cholesterol biosynthesis pathway. Reduced enzyme activity cause low levels of blood 1 6 2 cholesterol, as reported in patients affected by the Smith-Lemli-Opitz syndrome [12] . CYP7A1 gene is 1 6 3 involved in cholesterol catabolism and bile acids synthesis, mutations affecting this gene cause an increase of 1 6 4 total, hepatic cholesterol and a decrease in bile acids secretion [13] . 1 6 5
Performance assessment
The assessment approach used in this work was influenced by the methods used for the evaluation of tools 1 6 7 predicting the effect of variants on continuous phenotypes [14] . Model performance has been evaluated in 1 6 8 terms of distance and correlation, measuring the deviation from experimental values while assessing model 1 6 9 capability to predict a decrease or increase of cholesterol levels. The analysis has been conducted at two 1 7 0 levels. In the first part of the assessment, predictions were evaluated at the level of the single gene in order to 1 7 1 understand if prediction error was homogeneous or significantly different for some of the mutations. The 1 7 2 second part of the assessment focused on the overall performance of the predictor. In the first phase, the 1 7 3 analysis was focused on assessing model performance in terms of prediction error computed on each element 1 7 4 of the test set: the deviation was evaluated by computing the difference between predicted and experimental 1 7 5 data, in terms of the rate of cholesterol levels in case and control. This analysis was aimed to highlight 1 7 6 mutation effects that where under or over-predicted. In the second part of the assessment, model performance 1 7 7
has been evaluated in terms of correlation and error measures on the whole dataset. Correlation measures 1 7 8 used for the assessment has been: Pearson and Kendall's tau correlation coefficients. To better understand 1 7 9 the amount of variability described by the model compared to the variability inside the data, the R 2 index was 1 8 0 used. RMSE (Root Mean Squared Error) has been used in order to evaluate if the method predicting 1 8 1 cholesterol levels with huge deviation from real ones. A sensitivity analysis was performed on a set of rates, 1 8 2 corresponding to genes represented in the test set. The aim of this analysis was to understand the effect of a 1 8 3 perturbation of specific model parameters on the output [4] . In this case we decreased rates associated to 1 8 4 genes represented in the test set, using a reducing factor [0.1, 1] and measured model cholesterol levels when 1 8 5 a steady state was reached. 1 8 6
Results and discussion 1 8 7
Performance assessment on single genes mutations
The first part of the assessment was aimed to understand how the model performs on the single mutations 1 8 9
represented in the test set. This type of analysis highlighted cases where the model overestimated or 1 9 0 underestimated cholesterol levels, respectively called positive or negative errors. The error represent the 1 9 1 increase or decrease of cholesterol in case relative to controls (equation 1, 2, 3), which is not observed in 1 9 2 experimental data. The errors where divided by real data and converted to percentages as reported in Table 4 . 1 9 3
As already introduced, the datasets of patients have been divided in two sections. The first group of elements 1 9 4 of the test set is composed by patients affected by damaging mutations on genes that have a role in the onset 1 9 5 of the Autosomal Dominant Hypercholesterolemia: LDLR, APOB and APOE. The main effect of simulating 1 9 6 these mutations is an increase of blood cholesterol levels of LDL and decrease of HDL (Table 5) mutations in APOE, where the algorithm strongly underestimated the effect of damaging mutations on total 2 0 3 cholesterol levels. In this case a higher error has been registered for our optimized model (-53.1%) compared 2 0 4 with the former version (-27.4%). This situation is mainly related to the fact that the average levels of total 2 0 5 cholesterol of patients in the training set was lower than the one of the test set. 2 0 6
The effect of damaging mutations on the other genes of the test set have been simulated by reducing different 2 0 7 set of rates of the model. The model predicted the effect of ABCA1 mutations as a decrease in HDL levels, 2 0 8 but also produced overestimated decrease in LDL levels (Table 4) , which is not usually observed in patients 2 0 9 affected by related disease like Hypoalphalipoproteinemia [3] . CETP is a protein involved in the transport of 2 1 0 cholesterol esters from HDL to LDL, deficiency of this protein can cause a marked increase of HDL levels 2 1 1
[3]. In this case the model correctly predicted an increase in HDL cholesterol levels, with a bigger error 2 1 2 when optimized f mut was used (Table 4 ). The LCAT gene is involved in cholesterol esterification in HDL 2 1 3 particles, patients with mutations on this gene generally have low levels of HDL and LDL cholesterol [3] . In 2 1 4 this case the model was not able to accurately simulate HDL and LDL levels in all cases (Table 3) . 2 1 5
Explanation could be that it was not possible to train the parameter for patients with a homozygous mutation 2 1 6 on the LCAT gene (f mut has been assumed to be equal to 1). DHCR7 gene is involved in cholesterol 2 1 7 biosynthesis pathway, mutations reducing related enzymatic activity cause low levels of blood cholesterol 2 1 8
[12]. In all cases the model predicted a bigger decrease in total cholesterol levels with an error of -171.5%. 2 1 9 CYP7A1 gene is involved in cholesterol catabolism and bile acids synthesis, mutations affecting this gene 2 2 0 can cause an increase of total and hepatic cholesterol [13] . In this case the model generally predicted an 2 2 1 increase of LDL and total cholesterol levels and a decrease in HDL cholesterol. Nevertheless, CYP7A1 2 2 2 simulations showed an underestimation of LDL and total cholesterol levels ( Performance assessment on the overall dataset 2 3 3
The overall assessment highlighted that the training phase increased model performance (Table 6 ). Both 2 3 4
Pearson and Kendall correlation coefficients show that the use of trained f mut increased algorithm capability 2 3 5 to predict variations on cholesterol levels caused by gene mutations. In particular, HDL levels predicted by 2 3 6 the former version of the model have shown negative correlation with experimental values. The RMSE index 2 3 7 computed on HDL and total cholesterol levels has been decreased thanks to the training procedure, and the 2 3 8 same index on predicted LDL is one half of the one obtained with the original version of the model. R In this work we improved and assessed the performance of an in silico prediction method for blood 2 4 9 cholesterol levels. The addition of a training phase has generally improved model performance, as shown in 2 5 0 Table 6 . Our training phase overcomes the problem of model usability when no experimental data is 2 5 1 available for f mut parameters estimation. The reducing parameters presented by van de Pas and colleagues 2 5 2 were computed from variables obtained in wet lab experiments [6] . This procedure, in contrast with the 2 5 3 training methodology we applied in this work, did not take in account that decreasing different rates by the 2 5 4 same factor can lead to modification of cholesterol profiles with different magnitude. To better understand 2 5 5 model responses to different simulations, we performed a sensitivity analysis on the rates involved in the test 2 5 6 set (Fig 3) . This analysis showed that reduction of rate 5 and 7 produced a consistent decrease of model 2 5 7 predicted HDL, while increasing LDL and total cholesterol. The training procedure had computed f mut on the 2 5 8 basis of the difference between experimental levels and model response to the reduction of selected rates, as 2 5 9 previously explained. This procedure avoid an overestimation of the effect of mutations on the LDLR and 2 6 0 APOB genes, as observed when f mut based on experimental variables were used (Table 4 ). The use of trained 2 6 1 parameters has decreased prediction error when model was not able to correctly simulate the effect of a 2 6 2 mutated gene on cholesterol levels. In particular rate 9 regulates the flow of cholesterol from free to 2 6 3 esterified form in HDL particles, LCAT gene product activity. The effect of a mutation on this gene is 2 6 4 predicted by the model as an increase of HDL cholesterol while the opposite is observed in real data ( of genomic loci controlling cholesterol homeostasis, much of that still unknown, the effect of sex and 2 8 1 environmental factors that affects blood cholesterol levels, the possibility of developing a software able to 2 8 2 accurately predict cholesterol levels seems far from true. Hence we can consider the physiologically based in 2 8 3 silico model of human cholesterol metabolism, optimized in this work, as a useful tool for studying the effect 2 8 4 of damaging mutation on genes involved in cholesterol homeostasis 2 8 5 2 8 6 The effect of reducing model rates, involved in the test procedure, on HDL, LDL or total cholesterol levels 2 8 8 2 8 9 2 9 4 2 9 5
Z e a l a n d . 
